MLchartDataset catalogue

Patent · US11208630B2 · B2 · US

AAV production using suspension adapted cells

(11) Publication number
US11208630B2
(21) Application number
16/065,546
(22) Filing date
2016-12-23
(30) Priority date
2015-12-24
(43) Publication date
2021-12-28
(45) Date of grant
2021-12-28
(52) CPC
  • C12N Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media: 7/00, 15/86, 2710/16644, 2750/14151
(73) Assignee
UNIV FLORIDA
(54) Title
AAV production using suspension adapted cells
(57) Abstract

Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.

Full text
View on Google Patents

Claims (14)

  1. A method of producing recombinant AAV (rAAV) in suspension-adapted cells comprised in a medium, the method comprising supplementing the medium with between 5 mM and 200 mM sodium chloride (NaCl) prior to or at the same time as co-infecting the suspension-adapted cells with: a first recombinant herpes simplex virus (rHSV) encoding a gene of interest flanked by AAV inverted terminal repeats (ITRs), and a second rHSV encoding AAV rep and cap genes.
  2. The method of claim 1, further comprising diluting or changing the medium after co-infection such that the concentration of NaCl is decreased.
  3. The method of claim 2, wherein the diluting or changing the medium occurs 0.5-8 h after co-infection.
  4. The method of claim 1, wherein the concentration of supplemented NaCl is between 30 mM and 150 mM.
  5. The method of claim 1, wherein the concentration of NaCl is supplemented such that the total concentration of NaCl is between 130 mM and 200 mM.
  6. The method of claim 1, wherein the cells are mammalian or insect cells.
  7. The method of claim 1, wherein the cells containing the produced rAAV are harvested prior to cell lysis.
  8. The method of claim 7, wherein the step of harvesting the cells is performed by centrifugation.
  9. The method of claim 1, wherein the AAV ITRs are AAV-2 ITRs.
  10. The method of claim 1, wherein the suspension-adapted cells are suspension-adapted HEK293 cells.
  11. The method of claim 10, wherein the suspension-adapted HEK293 cells are derived from adherent HEK293 cells.
  12. The method of claim 1, further comprising isolating rAAV from the co-infected suspension-adapted cells.
  13. The method of claim 4, wherein the concentration of supplemented NaCl is between 60 mM to 90 mM.
  14. The method of claim 5, wherein the concentration of NaCl is supplemented such that the total concentration of NaCl is between 135 mM to 180 mM.

Citations (8)

  • US2005002908A1
  • US2009275107A1
  • US2014242671A1
  • US2015024467A1
  • US6416992B1
  • US6593123B1
  • US6989264B2
  • WO2015031686A1
Record as JSON
{
  "publication_number": "US11208630B2",
  "country": "US",
  "kind": "B2",
  "title": "AAV production using suspension adapted cells",
  "abstract": "Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.",
  "claims": [
    "1. A method of producing recombinant AAV (rAAV) in suspension-adapted cells comprised in a medium, the method comprising supplementing the medium with between 5 mM and 200 mM sodium chloride (NaCl) prior to or at the same time as co-infecting the suspension-adapted cells with: a first recombinant herpes simplex virus (rHSV) encoding a gene of interest flanked by AAV inverted terminal repeats (ITRs), and a second rHSV encoding AAV rep and cap genes.",
    "2. The method of claim 1, further comprising diluting or changing the medium after co-infection such that the concentration of NaCl is decreased.",
    "3. The method of claim 2, wherein the diluting or changing the medium occurs 0.5-8 h after co-infection.",
    "4. The method of claim 1, wherein the concentration of supplemented NaCl is between 30 mM and 150 mM.",
    "5. The method of claim 1, wherein the concentration of NaCl is supplemented such that the total concentration of NaCl is between 130 mM and 200 mM.",
    "6. The method of claim 1, wherein the cells are mammalian or insect cells.",
    "7. The method of claim 1, wherein the cells containing the produced rAAV are harvested prior to cell lysis.",
    "8. The method of claim 7, wherein the step of harvesting the cells is performed by centrifugation.",
    "9. The method of claim 1, wherein the AAV ITRs are AAV-2 ITRs.",
    "10. The method of claim 1, wherein the suspension-adapted cells are suspension-adapted HEK293 cells.",
    "11. The method of claim 10, wherein the suspension-adapted HEK293 cells are derived from adherent HEK293 cells.",
    "12. The method of claim 1, further comprising isolating rAAV from the co-infected suspension-adapted cells.",
    "13. The method of claim 4, wherein the concentration of supplemented NaCl is between 60 mM to 90 mM.",
    "14. The method of claim 5, wherein the concentration of NaCl is supplemented such that the total concentration of NaCl is between 135 mM to 180 mM."
  ],
  "cpc": [
    "C12N 7/00",
    "C12N 15/86",
    "C12N 2710/16644",
    "C12N 2750/14151"
  ],
  "assignees": [
    "UNIV FLORIDA"
  ],
  "filing_date": "2016-12-23",
  "publication_date": "2021-12-28",
  "grant_date": "2021-12-28",
  "priority_date": "2015-12-24",
  "application_number": "US-201616065546-A",
  "family_id": "59091228",
  "citations": [
    "US2005002908A1",
    "US2009275107A1",
    "US2014242671A1",
    "US2015024467A1",
    "US6416992B1",
    "US6593123B1",
    "US6989264B2",
    "WO2015031686A1"
  ]
}

Record 548 of 5,000 in Patents full text (MLC-0201). Request the full dataset.